Peritoneal Incretin Deficiency and Tirzepatide as a Multi-Axis Adjuvant Hypothesis in Treatment-Refractory Endometriosis: A Mechanistic Framework Linking Metabolism, Immunity, Fibrosis, and Nociception
Leonardo Jacobsen, Diogo Pinto da Costa Viana, Graciela Morgado Folador, Eduardo Schor, Adriana Luckow Invitti · 2026
Read Peritoneal Incretin Deficiency and Tirzepatide as a Multi-Axis Adjuvant Hypothesis in Treatment-Refractory Endometriosis: A Mechanistic Framework Linking Metabolism, Immunity, Fibrosis, and Nociception by Leonardo Jacobsen, Diogo Pinto da Costa Viana, Graciela Morgado Folador, Eduardo Schor, Adriana Luckow Invitti (2026) in the Tower of Babel, a free online library of public-domain works preserved in clean, searchable text. No sign-up. The full text is served as a plain-text file at a predictable URL, where text is present: https://antarctic-labs.com/tower-of-babel/PMC13362427.txt.
Description
Leonardo Jacobsen and co-authors set out a 2026 hypothesis paper on hard-to-treat endometriosis, a painful condition where womb-like tissue grows outside the womb. They suggest that low levels of gut hormones called incretins in the belly fluid may help keep the disease going. From that idea, they argue the diabetes drug tirzepatide, which boosts those hormones, might ease the disease on several fronts at once.
The paper maps how the drug could, in theory, curb cell fuel misuse, calm immune cells, slow scar-like tissue growth, and blunt pain signals. The authors are clear that no direct test in endometriosis exists yet. The piece is a plan for future lab and clinic work, not proof that the drug helps.
Catalog record
| CREATOR | Leonardo Jacobsen, Diogo Pinto da Costa Viana, Graciela Morgado Folador, Eduardo Schor, Adriana Luckow Invitti |
|---|---|
| YEAR | 2026 |
| COLLECTION | PAPERS |
| FORMAT | TXT |
| FILE SIZE | 64289 |
| LICENSE | https://creativecommons.org/licenses/by/4.0 |
| RIGHTS | CC BY |
| SOURCE | Europe PMC |